Shield Therapeutics ‘delivered an excellent first half’ with Accrufer powering ahead in the US

Shield Therapeutics PLC’s CEO, Greg Madison, talked to Proactive London about the strong results and growing momentum revealed in its half-year report.

Shield has executed on all three of its targets, he said, with a huge uptick in US prescriptions for anaemia treatment Accrufer feeding through into rising revenues.

Female health represented about 50% of total prescriptions, he adds, with roughly 1 in 5 women in the US suffering from an iron deficiency and offering a huge opportunity for Shield, he believes.

#anaemia #Accrufer #AIM #iron deficiency

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews